The Various Legal Actions Filed against Sanofi-Aventis

Posted by on Sep 16, 2016 in Taxotere Lawsuit | 0 comments

In various studies revolving around the different circumstances affecting women with breast cancer, hair loss consistently appeared as one of the most stressful side effects of cancer treatment, profoundly impacting affected patients’ well-being and quality of life.

It’s a relief that, in the case many women who have, or formerly had, breast cancer and had chemotherapy treatments, hair loss is only temporary as they can expect hair growth again up to six months after chemotherapy treatment. In the case of many women who were treated with Taxotere, however, it is not just a case of permanent baldness (a condition called alopecia or permanent hair loss), worse than this, it is rather a case of “alopecia universalis” or total hair loss on the scalp and body; this means that, aside from baldness, they have also lost their eyebrows and eyelashes, and hair growth under arms and around the genital area.

The law firm Williams Kherkher explains that, as early as 2005, patients outside of the U.S. were warned about permanent hair loss due to Taxotere use. Sanofi-Aventis, the said drug’s manufacturers, however, only began warning patients in the U.S. of this risk in December of 2015, after the U.S. food and Drug Administration (FDA) mandated them to do so.

Due to this, women who had been affected or alopecia or permanent hair loss have filed lawsuits against Sanofi-Aventis, claiming that the drug manufacturers:

  • Manufactured a dangerous drug;
  • Sold the drug without exhaustively testing it;
  • Sold the drug without disclosing the dangers or risks;
  • Failed to determine whether the drug was safe;
  • Failed to properly warn patients and health care providers;
  • Misled the public in advertising and marketing;
  • Concealed information from the public; and,
  • Downplayed the dangers associated with the drug.

Taxotere (Generic name: Docetaxel) is an intravenous chemotherapy drug manufactured by Sanofi-Aventis. It was approved by the U.S. Food and Drug Administration for the treatment of a variety of cancers including non-small cell lung cancer, prostate cancer, breast cancer, gastric cancer, and head and neck cancer. It was first approved for breast cancer treatment in 1996 then, in August 2004 the (FDA) approved it in combination with doxorubicin and cyclophosphamide for treatment of operable node-positive breast cancer in women.

Leave a Reply

Your email address will not be published. Required fields are marked *